BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ. Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET. Eur J Nucl Med Mol Imaging 2021;48:694-707. [PMID: 32889615 DOI: 10.1007/s00259-020-05002-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarcan ET, Paisey S, Ruthardt M, Ozer AY, Marshall C, Hartman N. 89Zr-labelled Obinutuzumab: a potential immuno-PET radiopharmaceutical. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08614-5] [Reference Citation Analysis]
2 Bubenshchikov VB, Larenkov AA. Chelating Agents for Zirconium-89 in the Synthesis of Radiopharmaceuticals: Current State and Prospects of Development. Russ J Coord Chem 2022;48:675-695. [DOI: 10.1134/s1070328422110021] [Reference Citation Analysis]
3 Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 36271158 DOI: 10.1007/s00259-022-05968-6] [Reference Citation Analysis]
4 Wuensche TE, Stergiou N, Mes I, Verlaan M, Schreurs M, Kooijman EJM, Janssen B, Windhorst AD, Jensen A, Asuni AA, Bang-Andersen B, Beaino W, Dongen GAMS, Vugts DJ. Advancing 89Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - The choice of chelator is essential. Theranostics 2022;12:7067-79. [PMID: 36276653 DOI: 10.7150/thno.73509] [Reference Citation Analysis]
5 Guo R, Xue S, Hu J, Sari H, Mingels C, Zeimpekis K, Prenosil G, Wang Y, Zhang Y, Viscione M, Sznitman R, Rominger A, Li B, Shi K. Using domain knowledge for robust and generalizable deep learning-based CT-free PET attenuation and scatter correction. Nat Commun 2022;13:5882. [PMID: 36202816 DOI: 10.1038/s41467-022-33562-9] [Reference Citation Analysis]
6 Allen KJH, Jiao R, Li J, Beckford-Vera DR, Dadachova E. In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule. Molecules 2022;27:6589. [PMID: 36235126 DOI: 10.3390/molecules27196589] [Reference Citation Analysis]
7 Damerow H, Cheng X, von Kiedrowski V, Schirrmacher R, Wängler B, Fricker G, Wängler C. Toward Optimized 89Zr-Immuno-PET: Side-by-Side Comparison of [89Zr]Zr-DFO-, [89Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [89Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable? Pharmaceutics 2022;14:2114. [PMID: 36297549 DOI: 10.3390/pharmaceutics14102114] [Reference Citation Analysis]
8 Bansal A, Sharma S, Klasen B, Rösch F, Pandey MK. Evaluation of different 89Zr-labeled synthons for direct labeling and tracking of white blood cells and stem cells in healthy athymic mice. Sci Rep 2022;12:15646. [PMID: 36123386 DOI: 10.1038/s41598-022-19953-4] [Reference Citation Analysis]
9 Southcott L, Wharton L, Rousseau J, Merkens H, Yang H, Bénard F, Orvig C. Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET. J Inorg Biochem 2022;235:111936. [PMID: 35878576 DOI: 10.1016/j.jinorgbio.2022.111936] [Reference Citation Analysis]
10 Fernandes EFA, Wilbs J, Raavé R, Jacobsen CB, Toftelund H, Helleberg H, Boswinkel M, Heskamp S, Gustafsson MBF, Bjørnsdottir I. Comparison of the Tissue Distribution of a Long-Circulating Glucagon-like Peptide-1 Agonist Determined by Positron Emission Tomography and Quantitative Whole-Body Autoradiography. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.2c00075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Bauer D, Visca H, Weerakkody A, Carter LM, Samuels Z, Kaminsky S, Andreev OA, Reshetnyak YK, Lewis JS. PET Imaging of Acidic Tumor Environment With 89Zr-labeled pHLIP Probes. Front Oncol 2022;12:882541. [DOI: 10.3389/fonc.2022.882541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Poels K, Schreurs M, Jansen M, Vugts DJ, Seijkens TTP, van Dongen GAMS, Lutgens E, Beaino W. Immuno-PET Imaging of Atherosclerotic Plaques with [89Zr]Zr-Anti-CD40 mAb—Proof of Concept. Biology 2022;11:408. [DOI: 10.3390/biology11030408] [Reference Citation Analysis]
13 Chen J, Wang J, Xu M, Jia X, Song G, Liu Z. Production of positron-emitting radionuclide yttrium-86 with a computer-aided design target for positron emission tomography. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gosmann D, Russelli L, Weber WA, Schwaiger M, Krackhardt AM, D'Alessandria C. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy. EJNMMI Res 2022;12:5. [PMID: 35099641 DOI: 10.1186/s13550-022-00877-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Damerow H, Hübner R, Judmann B, Schirrmacher R, Wängler B, Fricker G, Wängler C. Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability. Cancers (Basel) 2021;13:6349. [PMID: 34944969 DOI: 10.3390/cancers13246349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Russelli L, De Rose F, Leone L, Reder S, Schwaiger M, D'Alessandria C, Tei L. A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for 89Zr PET Imaging. Molecules 2021;26:5819. [PMID: 34641362 DOI: 10.3390/molecules26195819] [Reference Citation Analysis]
17 Feiner IVJ, Brandt M, Cowell J, Demuth T, Vugts D, Gasser G, Mindt TL. The Race for Hydroxamate-Based Zirconium-89 Chelators. Cancers (Basel) 2021;13:4466. [PMID: 34503276 DOI: 10.3390/cancers13174466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
18 Klasen B, Lemcke D, Mindt TL, Gasser G, Rösch F. Development and in vitro evaluation of new bifunctional 89Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications. Nucl Med Biol 2021;102-103:12-23. [PMID: 34242949 DOI: 10.1016/j.nucmedbio.2021.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Grus T, Lahnif H, Klasen B, Moon ES, Greifenstein L, Roesch F. Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy. Bioconjug Chem 2021;32:1223-31. [PMID: 34170116 DOI: 10.1021/acs.bioconjchem.1c00305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
20 Guillou A, Earley DF, Klingler S, Nisli E, Nüesch LJ, Fay R, Holland JP. The Influence of a Polyethylene Glycol Linker on the Metabolism and Pharmacokinetics of a 89Zr-Radiolabeled Antibody. Bioconjug Chem 2021;32:1263-75. [PMID: 34056896 DOI: 10.1021/acs.bioconjchem.1c00172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
21 Chomet M, van Dongen GAMS, Vugts DJ. State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET. Bioconjug Chem 2021;32:1315-30. [PMID: 33974403 DOI: 10.1021/acs.bioconjchem.1c00136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
22 Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, Zeglis BM. Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjug Chem 2021;32:1255-62. [PMID: 33835770 DOI: 10.1021/acs.bioconjchem.1c00121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Brown CJM, Codd R. Directing macrocyclic architecture using iron(III)-, gallium(III)-, or zirconium(IV)-assisted ring closure of linear dimeric endo-hydroxamic acid ligands. J Inorg Biochem 2021;216:111337. [PMID: 33360106 DOI: 10.1016/j.jinorgbio.2020.111337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, van Kuijk C, Boellaard R, Huisman MC, Vugts DJ. The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. J Nucl Med 2021;62:438-45. [PMID: 33277395 DOI: 10.2967/jnumed.119.239558] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]